Glück Conviction Score™ ⓘ
LGND
LIGAND PHARMACEUTICALS INC
🟢
Conviction × Timing — fundamental hohe Conviction trifft auf ein positiv drehendes Timing (Momentum/FTD). Der günstige Quadrant des Modells.
Effektiv: Stark
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
67,0
53 neu, 134 erhöht, -12226K $ netto
Aktivist
28,3
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 226.13 | +13.0 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 199.39 | +28.2 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 236.58 | EMA50: 226.52 | |
| MACD-Histogramm | Bullisch | 10 % | 2.377 | Bullisch | |
| RSI(14) | Bärisch | 10 % | 73.3 | Überkauft | |
| Stoch %K(14) | Bärisch | 5 % | 90.4 | Überkauft | |
| ADX(14)+DI | Neutral | 10 % | 22.1 | +DI: 32.2 / −DI: 13.0 | |
| Z-Score(60) | Bärisch | 5 % | 2.24 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 100.0 % | Hoch 255.54 / Tief 112.50 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 94.6 % | Upper 258.33 / Mid 232.26 / Lower 206.19 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.6590 | R²=0.58 / annualisiert +74.8 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | Aryeh Jason | Director | Open Market Sale | -4.500 | 250,00 | -1.125.000,00 | -721,4% | |
| 2026-06-10 | Aryeh Jason | Director | Open Market Sale | -500 | 250,00 | -125.000,00 | -80,2% | |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open Market Sale | -3.405 | 251,62 | -856.751,80 | -549,4% | |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open Market Sale | -697 | 249,53 | -173.924,22 | -111,5% | |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open Market Sale | -257 | 247,22 | -63.536,49 | -40,7% | |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open Market Sale | -232 | 248,11 | -57.561,78 | -36,9% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -200 | 230,41 | -46.082,00 | -29,6% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -400 | 226,78 | -90.711,76 | -58,2% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.432 | 225,97 | -323.585,03 | -207,5% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.216 | 229,47 | -279.032,60 | -178,9% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -677 | 225,20 | -152.459,25 | -97,8% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -584 | 228,57 | -133.487,10 | -85,6% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -491 | 223,95 | -109.957,83 | -70,5% | |
| 2026-05-13 | KOZARICH JOHN W | Director | Open Market Sale | -1.575 | 223,50 | -352.012,50 | -225,7% | |
| 2026-05-12 | KOZARICH JOHN W | Director | Open Market Sale | -459 | 224,00 | -102.816,00 | -65,9% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -600 | 227,45 | -136.469,58 | -87,5% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -165 | 231,87 | -38.258,07 | -24,5% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -116 | 234,09 | -27.153,89 | -17,4% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -105 | 232,57 | -24.419,89 | -15,7% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -80 | 227,37 | -18.189,40 | -11,7% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -1 | 229,87 | -229,87 | -0,1% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.420 | 232,92 | -330.749,24 | -212,1% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -932 | 228,75 | -213.198,45 | -136,7% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -800 | 234,02 | -187.214,16 | -120,1% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -780 | 232,04 | -180.991,12 | -116,1% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -370 | 230,87 | -85.421,60 | -54,8% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -98 | 229,71 | -22.511,44 | -14,4% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -40 | 201,24 | -8.049,40 | -5,2% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.302 | 199,72 | -260.038,17 | -166,8% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.238 | 200,94 | -248.767,31 | -159,5% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -963 | 203,22 | -195.702,59 | -125,5% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -700 | 201,90 | -141.327,97 | -90,6% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -460 | 198,85 | -91.470,68 | -58,7% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -337 | 204,50 | -68.917,38 | -44,2% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -159 | 204,26 | -32.477,77 | -20,8% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -146 | 199,97 | -29.196,34 | -18,7% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -79 | 202,42 | -15.991,36 | -10,3% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -43 | 202,91 | -8.725,22 | -5,6% | |
| 2026-03-23 | Sabba Stephen L | Director | Open Market Sale | -1.000 | 207,87 | -207.872,70 | -133,3% | |
| 2026-03-11 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -3.057 | 225,00 | -687.825,00 | -441,1% | |
| 2026-03-06 | LAMATTINA JOHN L | Director | Open Market Sale | -2.161 | 200,76 | -433.842,36 | -278,2% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -3.413 | 208,80 | -712.620,75 | -457,0% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -93 | 200,62 | -18.657,89 | -12,0% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -100 | 197,70 | -19.769,54 | -12,7% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -100 | 199,01 | -19.900,50 | -12,8% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -200 | 204,17 | -40.834,00 | -26,2% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -207 | 199,96 | -41.390,89 | -26,5% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -300 | 201,70 | -60.510,00 | -38,8% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -340 | 206,37 | -70.164,78 | -45,0% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -460 | 205,18 | -94.381,88 | -60,5% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -612 | 207,01 | -126.689,45 | -81,2% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.142 | 208,87 | -238.532,28 | -153,0% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.446 | 208,12 | -300.939,06 | -193,0% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -53 | 200,08 | -10.604,12 | -6,8% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -668 | 203,63 | -136.023,97 | -87,2% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -697 | 202,79 | -141.342,75 | -90,6% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -698 | 201,09 | -140.363,54 | -90,0% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -699 | 198,71 | -138.894,93 | -89,1% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -743 | 204,74 | -152.125,46 | -97,6% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -950 | 201,73 | -191.640,27 | -122,9% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -1.457 | 205,79 | -299.841,42 | -192,3% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -1.588 | 206,89 | -328.541,96 | -210,7% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -2.457 | 207,91 | -510.823,08 | -327,6% | |
| 2026-03-03 | Sabba Stephen L | Director | Open Market Sale | -2.034 | 201,50 | -409.851,00 | -262,8% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -204 | 199,69 | -40.736,64 | -26,1% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -41 | 200,40 | -8.216,56 | -5,3% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -50 | 202,54 | -10.126,94 | -6,5% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -47 | 197,14 | -9.265,57 | -5,9% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -42 | 203,57 | -8.549,94 | -5,5% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -83 | 201,65 | -16.736,72 | -10,7% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -23 | 195,61 | -4.498,92 | -2,9% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -381 | 196,36 | -74.814,46 | -48,0% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -39 | 191,00 | -7.449,00 | -4,8% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -23 | 197,20 | -4.535,49 | -2,9% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -1 | 192,18 | -192,18 | -0,1% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -46 | 192,40 | -8.850,17 | -5,7% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -207 | 190,27 | -39.385,95 | -25,3% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -102 | 188,96 | -19.274,20 | -12,4% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -91 | 187,95 | -17.103,78 | -11,0% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -21 | 186,59 | -3.918,39 | -2,5% | |
| 2025-12-12 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -1.804 | 188,31 | -339.711,24 | -217,9% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -179 | 194,76 | -34.861,72 | -22,4% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -4 | 196,35 | -785,38 | -0,5% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -92 | 197,72 | -18.189,95 | -11,7% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -92 | 193,86 | -17.834,91 | -11,4% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -47 | 195,80 | -9.202,54 | -5,9% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -30 | 200,02 | -6.000,46 | -3,8% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -23 | 199,22 | -4.581,95 | -2,9% | |
| 2025-11-07 | Gray Nancy Ryan | Director | Open Market Sale | -3.015 | 205,45 | -619.431,75 | -397,2% | |
| 2025-11-07 | LAMATTINA JOHN L | Director | Open Market Sale | -2.145 | 205,45 | -440.690,25 | -282,6% | |
| 2025-11-07 | LAMATTINA JOHN L | Director | Open Market Sale | -2.034 | 205,45 | -417.885,30 | -268,0% | |
| 2025-11-07 | Gray Nancy Ryan | Director | Open Market Sale | -3.556 | 205,45 | -730.580,20 | -468,5% | |
| 2025-11-03 | KOZARICH JOHN W | Director | Open Market Sale | -207 | 191,25 | -39.588,63 | -25,4% | |
| 2025-11-03 | KOZARICH JOHN W | Director | Open Market Sale | -84 | 189,00 | -15.875,73 | -10,2% | |
| 2025-11-03 | KOZARICH JOHN W | Director | Open Market Sale | -127 | 192,38 | -24.432,02 | -15,7% | |
| 2025-11-03 | KOZARICH JOHN W | Director | Open Market Sale | -49 | 190,26 | -9.322,64 | -6,0% | |
| 2025-10-01 | KOZARICH JOHN W | Director | Open Market Sale | -155 | 180,01 | -27.901,52 | -17,9% | |
| 2025-10-01 | KOZARICH JOHN W | Director | Open Market Sale | -24 | 177,60 | -4.262,52 | -2,7% | |
| 2025-10-01 | KOZARICH JOHN W | Director | Open Market Sale | -196 | 178,41 | -34.967,40 | -22,4% | |
| 2025-10-01 | KOZARICH JOHN W | Director | Open Market Sale | -92 | 181,18 | -16.668,91 | -10,7% | |
| 2025-09-23 | Aryeh Jason | Director | Open Market Sale | -954 | 171,92 | -164.015,21 | -105,2% | |
| 2025-09-23 | Aryeh Jason | Director | Open Market Sale | -4.628 | 170,96 | -791.222,78 | -507,4% | |
| 2025-09-23 | Aryeh Jason | Director | Open Market Sale | -4.418 | 170,41 | -752.849,73 | -482,8% | |
| 2025-09-02 | KOZARICH JOHN W | Director | Open Market Sale | -267 | 161,51 | -43.124,10 | -27,7% | |
| 2025-09-02 | KOZARICH JOHN W | Director | Open Market Sale | -85 | 164,25 | -13.961,08 | -9,0% | |
| 2025-09-02 | KOZARICH JOHN W | Director | Open Market Sale | -115 | 162,52 | -18.689,66 | -12,0% | |
| 2025-08-01 | KOZARICH JOHN W | Director | Open Market Sale | -467 | 131,88 | -61.585,86 | -39,5% | |
| 2025-07-10 | KOZARICH JOHN W | Director | Open Market Sale | -934 | 125,00 | -116.750,00 | -74,9% | |
| 2025-06-23 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -500 | 114,08 | -57.042,15 | -36,6% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 2.961.923 | 2.940.231 | 21.692 | 591.347.927 | Aufgestockt | +0,7% | |
| VANGUARD GROUP INC | 2.073.892 | 0 | 2.073.892 | 392.110.761 | Neu | +100,0% | |
| JANUS HENDERSON GROUP PLC | 1.009.891 | 995.400 | 14.491 | 201.622.937 | Aufgestockt | +1,5% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 848.089 | 0 | 848.089 | 169.320.969 | Neu | +100,0% | |
| Invesco Ltd. | 823.604 | 516.464 | 307.140 | 164.432.539 | Aufgestockt | +59,5% | |
| STATE STREET CORP | 778.856 | 751.205 | 27.651 | 155.498.600 | Aufgestockt | +3,7% | |
| FMR LLC | 596.127 | 579.155 | 16.972 | 119.016.815 | Aufgestockt | +2,9% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 573.312 | 644.093 | -70.781 | 114.462.000 | Reduziert | -11,0% | |
| FRANKLIN RESOURCES INC | 573.177 | 496.160 | 77.017 | 114.434.772 | Aufgestockt | +15,5% | |
| Chicago Capital, LLC | 561.675 | 561.423 | 252 | 112.138.378 | Aufgestockt | 0,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 558.934 | 493.589 | 65.345 | 111.608.727 | Aufgestockt | +13,2% | |
| CONGRESS ASSET MANAGEMENT CO | 504.637 | 480.063 | 24.574 | 100.750.777 | Aufgestockt | +5,1% | |
| Stephens Investment Management Group LLC | 494.670 | 501.040 | -6.370 | 98.760.866 | Reduziert | -1,3% | |
| DIMENSIONAL FUND ADVISORS LP | 425.230 | 432.992 | -7.762 | 84.887.195 | Reduziert | -1,8% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 411.543 | 507.019 | -95.476 | 82.164.560 | Reduziert | -18,8% | |
| GOLDMAN SACHS GROUP INC | 381.111 | 429.004 | -47.893 | 76.088.811 | Reduziert | -11,2% | |
| LOOMIS SAYLES & CO L P | 353.209 | 382.677 | -29.468 | 70.518.177 | Reduziert | -7,7% | |
| DEUTSCHE BANK AG\ | 306.111 | 307.871 | -1.760 | 61.115.061 | Reduziert | -0,6% | |
| VICTORY CAPITAL MANAGEMENT INC | 303.224 | 256.410 | 46.814 | 60.538.672 | Aufgestockt | +18,3% | |
| RICE HALL JAMES & ASSOCIATES, LLC | 283.567 | 279.627 | 3.940 | 56.614.152 | Aufgestockt | +1,4% | |
| Ranger Investment Management, L.P. | 267.943 | 269.983 | -2.040 | 53.494.820 | Reduziert | -0,8% | |
| NORTHERN TRUST CORP | 254.158 | 250.640 | 3.518 | 50.742.645 | Aufgestockt | +1,4% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 212.888 | 363.584 | -150.696 | 42.503.090 | Reduziert | -41,4% | |
| ASHFORD CAPITAL MANAGEMENT INC | 207.565 | 213.778 | -6.213 | 41.440.352 | Reduziert | -2,9% | |
| Private Capital Management, LLC | 201.381 | 208.891 | -7.510 | 40.205.717 | Reduziert | -3,6% | |
| VILLERE ST DENIS J & CO LLC | 188.874 | 202.452 | -13.578 | 37.708.694 | Reduziert | -6,7% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 182.887 | 184.284 | -1.397 | 36.513.390 | Reduziert | -0,8% | |
| MORGAN STANLEY | 167.229 | 193.402 | -26.173 | 33.387.355 | Reduziert | -13,5% | |
| BANK OF AMERICA CORP /DE/ | 157.865 | 120.169 | 37.696 | 31.517.680 | Aufgestockt | +31,4% | |
| Impax Asset Management Group plc | 152.444 | 165.208 | -12.764 | 30.435.445 | Reduziert | -7,7% | |
| Fiera Capital Corp | 135.312 | 131.236 | 4.076 | 27.015.040 | Aufgestockt | +3,1% | |
| Fisher Asset Management, LLC | 127.994 | 130.858 | -2.864 | 25.554.038 | Reduziert | -2,2% | |
| Russell Investments Group, Ltd. | 121.151 | 138.464 | -17.313 | 24.187.856 | Reduziert | -12,5% | |
| NEW YORK STATE COMMON RETIREMENT FUND | 119.839 | 107.530 | 12.309 | 23.925.856 | Aufgestockt | +11,4% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 118.169 | 122.326 | -4.157 | 23.592.441 | Reduziert | -3,4% | |
| NOMURA HOLDINGS INC | 114.355 | 116.417 | -2.062 | 22.830.976 | Reduziert | -1,8% | |
| ROYAL BANK OF CANADA | 111.543 | 108.796 | 2.747 | 22.270.000 | Aufgestockt | +2,5% | |
| UBS Group AG | 104.580 | 143.067 | -38.487 | 20.879.398 | Reduziert | -26,9% | |
| Legal & General Group Plc | 97.660 | 108.383 | -10.723 | 19.497.821 | Reduziert | -9,9% | |
| NEXT CENTURY GROWTH INVESTORS LLC | 95.876 | 0 | 95.876 | 19.141.643 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 95.716 | 93.830 | 1.886 | 19.109.700 | Aufgestockt | +2,0% | |
| Penn Capital Management Company, LLC | 95.456 | 98.848 | -3.392 | 19.077.735 | Reduziert | -3,4% | |
| Clark Capital Management Group, Inc. | 90.206 | 79.778 | 10.428 | 18.009.628 | Aufgestockt | +13,1% | |
| Aberdeen Group plc | 90.044 | 119.309 | -29.265 | 17.977.284 | Reduziert | -24,5% | |
| D. E. Shaw & Co., Inc. | 87.228 | 44.151 | 43.077 | 17.415.070 | Aufgestockt | +97,6% | |
| BANK OF MONTREAL /CAN/ | 86.183 | 126.063 | -39.880 | 17.206.436 | Reduziert | -31,6% | |
| WELLS FARGO & COMPANY/MN | 84.901 | 132.636 | -47.735 | 16.950.385 | Reduziert | -36,0% | |
| FIRST TRUST ADVISORS LP | 80.401 | 69.220 | 11.181 | 16.052.059 | Aufgestockt | +16,2% | |
| AMERIPRISE FINANCIAL INC | 77.273 | 98.264 | -20.991 | 15.427.556 | Reduziert | -21,4% | |
| SEI INVESTMENTS CO | 75.188 | 46.368 | 28.820 | 15.011.511 | Aufgestockt | +62,2% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2.961.923 | 2.940.231 | +0,7% | 591.347.927 | 15,55 |
| JANUS HENDERSON GROUP PLC | 1.009.891 | 995.400 | +1,5% | 201.622.937 | 5,30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 848.089 | 0 | +100,0% | 169.320.969 | 4,45 |
| Invesco Ltd. | 823.604 | 516.464 | +59,5% | 164.432.539 | 4,32 |
| STATE STREET CORP | 778.856 | 751.205 | +3,7% | 155.498.600 | 4,09 |
| FMR LLC | 596.127 | 579.155 | +2,9% | 119.016.815 | 3,13 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 573.312 | 644.093 | -11,0% | 114.462.000 | 3,01 |
| FRANKLIN RESOURCES INC | 573.177 | 496.160 | +15,5% | 114.434.772 | 3,01 |
| Chicago Capital, LLC | 561.675 | 561.423 | 0,0% | 112.138.378 | 2,95 |
| GEODE CAPITAL MANAGEMENT, LLC | 558.934 | 493.589 | +13,2% | 111.608.727 | 2,93 |
| CONGRESS ASSET MANAGEMENT CO | 504.637 | 480.063 | +5,1% | 100.750.777 | 2,65 |
| Stephens Investment Management Group LLC | 494.670 | 501.040 | -1,3% | 98.760.866 | 2,60 |
| DIMENSIONAL FUND ADVISORS LP | 425.230 | 432.992 | -1,8% | 84.887.195 | 2,23 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 411.543 | 507.019 | -18,8% | 82.164.560 | 2,16 |
| GOLDMAN SACHS GROUP INC | 381.111 | 429.004 | -11,2% | 76.088.811 | 2,00 |
| LOOMIS SAYLES & CO L P | 353.209 | 382.677 | -7,7% | 70.518.177 | 1,85 |
| DEUTSCHE BANK AG\ | 306.111 | 307.871 | -0,6% | 61.115.061 | 1,61 |
| VICTORY CAPITAL MANAGEMENT INC | 303.224 | 256.410 | +18,3% | 60.538.672 | 1,59 |
| RICE HALL JAMES & ASSOCIATES, LLC | 283.567 | 279.627 | +1,4% | 56.614.152 | 1,49 |
| Ranger Investment Management, L.P. | 267.943 | 269.983 | -0,8% | 53.494.820 | 1,41 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 352 | 22,6 | 4.429 |
| 31.12.2025 | ✓ | 342 | 21,3 | 3.949 |
| 30.09.2025 | ✓ | 313 | 37,0 | 3.675 |
| 30.06.2025 | ✓ | 265 | 19,2 | 2.137 |
| 31.03.2025 | ✓ | 257 | 20,1 | 2.029 |
| 31.12.2024 | ✓ | 254 | 18,8 | 1.929 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 644.093 | 121.779.000 |
| Fiera Capital Corp | 131.236 | 24.812.790 |
| WCM INVESTMENT MANAGEMENT, LLC | 45.621 | 8.677.114 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 20.036 | 3.788.207 |
| One Capital Management, LLC | 9.287 | 1.755.893 |
| Future Fund LLC | 9.280 | 1.754.570 |
| XTX Topco Ltd | 7.717 | 1.459.053 |
| B. Metzler seel. Sohn & Co. AG | 6.879 | 1.300.613 |
| Connor, Clark & Lunn Investment Management Ltd. | 6.033 | 1.140.659 |
| GUGGENHEIM CAPITAL LLC | 5.257 | 993.941 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| FRANKLIN RESOURCES INC | 496.160 | 266.304 | +115.9 % | 93.808.984 |
| Invesco Ltd. | 516.464 | 138.169 | +36.5 % | 97.647.849 |
| FMR LLC | 579.155 | 121.924 | +26.7 % | 109.500.870 |
| GW&K Investment Management, LLC | 117.432 | 85.297 | +265.4 % | 22.204 |
| GOLDMAN SACHS GROUP INC | 429.004 | 61.209 | +16.6 % | 81.111.786 |
| BlackRock, Inc. | 2.940.231 | 55.704 | +1.9 % | 555.909.475 |
| UBS Group AG | 143.067 | 31.081 | +27.8 % | 27.049.678 |
| BNP PARIBAS FINANCIAL MARKETS | 34.957 | 30.865 | +754.3 % | 6.609.320 |
| D. E. Shaw & Co., Inc. | 44.151 | 25.037 | +131.0 % | 8.347.630 |
| BESSEMER GROUP INC | 23.510 | 22.764 | +3051.5 % | 4.444 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| CONGRESS ASSET MANAGEMENT CO | 480.063 | -187.248 | -28.1 % | 90.765.511 |
| DIMENSIONAL FUND ADVISORS LP | 432.992 | -90.921 | -17.4 % | 81.867.024 |
| VILLERE ST DENIS J & CO LLC | 202.452 | -77.498 | -27.7 % | 38.277.599 |
| Aberdeen Group plc | 119.309 | -70.439 | -37.1 % | 22.557.752 |
| Stephens Investment Management Group LLC | 501.040 | -53.502 | -9.6 % | 94.731.633 |
| JANUS HENDERSON GROUP PLC | 995.400 | -46.978 | -4.5 % | 188.199.064 |
| OSAIC HOLDINGS, INC. | 59.405 | -41.337 | -41.0 % | 11.231.696 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 122.326 | -40.475 | -24.9 % | 23.128.177 |
| JANE STREET GROUP, LLC | 24.162 | -38.897 | -61.7 % | 4.568.309 |
| Allspring Global Investments Holdings, LLC | 71.818 | -36.606 | -33.8 % | 13.653.320 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 01.05.2026 | Vanguard Portfolio Management | Passiv (13G) | 5,56 % | 1.109.154 | Neu | |
| 01.05.2026 | Vanguard Capital Management | Passiv (13G) | 5,00 % | 997.637 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,76 pp | |
| 14.11.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,30 % | 1.042.378 | -0,20 pp | |
| 17.10.2025 | BlackRock, Inc. | Passiv (13G/A) | 14,50 % | 2.839.251 | -1,10 pp | |
| 14.08.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,50 % | 1.060.734 | +0,20 pp | |
| 14.05.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,30 % | 1.028.066 | -0,10 pp | |
| 14.02.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,40 % | 1.015.023 | Neu | |
| 05.02.2025 | BlackRock, Inc. | Passiv (13G/A) | 15,60 % | 2.945.939 | Neu | |
| 14.11.2024 | Janus Henderson Group plc | Passiv (13G/A) | 5,50 % | 1.009.094 | -2,20 pp | |
| 08.11.2024 | GOLDMAN SACHS & CO. LLC | Passiv (13G/A) | 0,30 % | 52.350 | -6,50 pp | |
| 08.11.2024 | THE GOLDMAN SACHS GROUP, INC. | Passiv (13G/A) | 0,30 % | 52.350 | -6,50 pp | |
| 01.11.2024 | Macquarie Group Limited | Passiv (13G/A) | 4,86 % | 887.275 | -0,80 pp | |
| 01.11.2024 | Macquarie Management Holdings Inc | Passiv (13G/A) | 4,86 % | 887.275 | -0,80 pp | |
| 01.11.2024 | Macquarie Investment Management Business Trust | Passiv (13G/A) | 4,86 % | 887.275 | -0,80 pp | |
| 14.02.2024 | Macquarie Group Limited | Passiv (13G) | 5,66 % | 987.248 | Neu | |
| 14.02.2024 | Macquarie Management Holdings Inc | Passiv (13G) | 5,66 % | 987.248 | Neu | |
| 14.02.2024 | Macquarie Investment Management Business Trust | Passiv (13G) | 5,66 % | 987.248 | Neu | |
| 13.02.2024 | Janus Henderson Triton Fund | Passiv (13G/A) | 5,10 % | 897.906 | -0,20 pp | |
| 13.02.2024 | Janus Henderson Group plc | Passiv (13G/A) | 7,70 % | 1.343.154 | +0,30 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 10,76 % | 1.876.514 | -0,15 pp | |
| 12.02.2024 | THE GOLDMAN SACHS GROUP, INC. | Passiv (13G) | 6,80 % | 1.181.931 | Neu | |
| 12.02.2024 | GOLDMAN SACHS & CO. LLC | Passiv (13G) | 6,80 % | 1.181.931 | Neu | |
| 22.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 17,00 % | 2.962.094 | +0,50 pp | |
| 10.02.2023 | Janus Henderson Group plc | Passiv (13G/A) | 7,40 % | 1.255.273 | -1,20 pp | |
| 10.02.2023 | Janus Henderson Triton Fund | Passiv (13G/A) | 5,30 % | 897.906 | -0,70 pp | |
| 09.02.2023 | William Blair Investment Management, LLC | Passiv (13G/A) | 0,80 % | 141.128 | -7,60 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 10,91 % | 1.843.115 | +0,64 pp | |
| 06.02.2023 | : STATE STREET CORPORATION | Passiv (13G/A) | 3,85 % | 0 | -1,46 pp | |
| 26.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,50 % | 2.789.479 | 0,00 pp | |
| 20.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,50 % | 2.789.479 | +0,10 pp | |
| 14.02.2022 | Macquarie Group Limited | Passiv (13G/A) | 3,74 % | 624.969 | -1,94 pp | |
| 14.02.2022 | Macquarie Investment Management Business Trust | Passiv (13G/A) | 3,74 % | 624.720 | Neu | |
| 14.02.2022 | Macquarie Investment Management Global Limited | Passiv (13G/A) | 0,00 % | 249 | Neu | |
| 14.02.2022 | Macquarie Management Holdings Inc | Passiv (13G/A) | 3,74 % | 624.720 | Neu | |
| 14.02.2022 | Cardinal Capital Management, LLC | Passiv (13G/A) | 1,00 % | 162.608 | -5,80 pp | |
| 11.02.2022 | : STATE STREET CORPORATION | Passiv (13G/A) | 5,31 % | 0 | -1,94 pp | |
| 10.02.2022 | Janus Henderson Triton Fund | Passiv (13G/A) | 6,00 % | 1.010.358 | -0,70 pp | |
| 10.02.2022 | Janus Henderson Group plc | Passiv (13G/A) | 8,60 % | 1.441.085 | -1,40 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 10,27 % | 1.716.735 | -0,06 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 29.05.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 03.03.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 15.01.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 05.01.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Ligand Pharmaceuticals Incorporated, ein Biopharmaka-Unternehmen, konzentriert sich auf die Entwicklung oder Übernahme von Technologien, die Pharmaunternehmen bei der Entdeckung und Entwicklung von Arzneimitteln weltweit unterstützen. Seine kommerziellen Programme umfassen Kyprolis und Evomela zur Behandlung des multiplen Myeloms; Veklury zur Behandlung von moderater bis schwerer COVID-19; Teriparatid-Injektionsprodukt gegen Osteoporose; Vaxneuvance zur Prävention invasiver Erkrankungen, die durch Streptococcus pneumoniae verursacht werden; und Pneumosil, ein Pneumokokken-Konjugatimpfstoff zur Prävention von Pneumokokken-Pneumonie bei Kindern. Das Unternehmen bietet auch Rylaze, eine rekombinante Erwinia-Asparaginase zur Behandlung akuter lymphoblastischer Leukämie oder lymphoblastischer Lymphome bei erwachsenen und pädiatrischen Patienten; und Nexterone, eine Captisol-Formulierung von Amiodaron; sowie Zulresso, eine Captisol-Formulierung von Brexanolon zur Behandlung von postpartaler Depression. Darüber hinaus bietet das Unternehmen Noxafil-IV, eine Captisol-Formulierung von Posaconazol zur intravenösen Anwendung; Duavee zur Behandlung von postmenopausaler Osteoporose; das Aziyo-Portfolio von kommerziellen Perikardmittel- und CanGaroo-Hüllenextrazellularmatrixprodukten; Exemptia gegen Autoimmunerkrankungen; Vivitra gegen Brustkrebs; Bryxta und Zybev gegen verschiedene Indikationen; und Minnebro zur Behandlung von Hypertonie. Die Partner- und Lizenzprogramme des Unternehmens, die sich in klinischer Entwicklung befinden, werden zur Behandlung von Krebs, Anfallsleiden, Diabetes, Herz-Kreislauf-Erkrankungen, Muskelschwund, Leber- und Nierenerkrankungen und anderen Erkrankungen verwendet. Darüber hinaus verkauft das Unternehmen Captisol-Materialien. Das Unternehmen wurde 1987 gegründet und hat seinen Sitz in Emeryville, Kalifornien.
Unternehmen & Branche
| Name | LIGAND PHARMACEUTICALS INC |
|---|---|
| Ticker | LGND |
| CIK | 0000886163 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 53220K215 |
|---|---|
| ISIN | US53220K2151 |
| Typ | Common Stock |
| Marktkapitalisierung | 4,91 Mrd. USD |
| KGV (P/E) | 40,50 |
| Beta | 1,23 |
| Dividendenrendite | 0,01 % |
Bewertung
| KBV (P/B) | 4,83 vs. 3,15 (2021) ▲ |
|---|---|
| KUV (P/S) | 18,31 vs. 10,72 (2021) ▲ |
| EV/EBITDA | 63,4 vs. 16,6 (2021) ▲ |
| FCF-Rendite | 1,0 % vs. 2,7 % (2021) ▼ |
| Buyback-Rendite | 0,3 % vs. 0,0 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | 15,3 % vs. 43,0 % (2021) ▼ |
|---|---|
| Nettomarge | 46,4 % vs. 23,7 % (2021) ▲ |
| ROIC | 12,2 % vs. 6,9 % (2021) ▲ |
| Nettoverschuldung/EBITDA | -2,3 vs. -0,1 (2021) ▼ |
| Zinsdeckungsgrad | 8,7 vs. 5,3 (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 3,15 | 1,90 | 1,79 | 2,47 | 3,68 | |
| KUV (P/S) | 10,72 | 5,77 | 9,55 | 12,25 | 13,95 | |
| EV/EBITDA | 16,6 | 20,1 | 25,5 | 156,9 | 47,7 | |
| FCF-Rendite | 2,7 % | 10,6 % | 3,7 % | 4,7 % | 1,3 % | |
| Buyback-Rendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,4 % | |
| Qualität & Bilanz | ||||||
| Operative Marge | 43,0 % | 1,5 % | 9,1 % | -13,5 % | 15,3 % | |
| Nettomarge | 23,7 % | -17,0 % | 39,7 % | -2,4 % | 46,4 % | |
| ROIC | 6,9 % | -5,5 % | 7,4 % | -0,5 % | 12,2 % | |
| Nettoverschuldung/EBITDA | -0,1 | -0,6 | -0,3 | -5,2 | -2,3 | |
| Zinsdeckungsgrad | 5,3 | 1,7 | 18,2 | -7,4 | 8,7 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 51.722.000 | -13.345.000 | -0,67 | 1.532.105.000 | 997.322.000 |
| 2025-12-31 | 10-K | 268.087.000 | 124.453.000 | 6,13 | 1.560.637.000 | 1.017.212.000 |
| 2025-09-30 | 10-Q | 115.461.000 | 117.273.000 | 5,68 | 1.476.772.000 | 950.171.000 |
| 2025-06-30 | 10-K | 53.100.000 | ||||
| 2025-06-30 | 10-Q | 53.100.000 | 4.847.000 | 0,24 | 948.604.000 | 828.529.000 |
| 2025-03-31 | 10-Q | 45.333.000 | -42.451.000 | -2,21 | 905.435.000 | 795.534.000 |
| 2024-12-31 | 10-K | 167.133.000 | -4.032.000 | -0,22 | 941.774.000 | 830.439.000 |
| 2024-09-30 | 10-Q | 51.812.000 | -7.172.000 | -0,39 | 954.866.000 | 841.178.000 |
| 2024-06-30 | 10-Q | 41.531.000 | -51.911.000 | -2,88 | 866.405.000 | 775.198.000 |
| 2024-03-31 | 10-Q | 30.978.000 | 86.139.000 | 4,75 | 913.869.000 | 806.521.000 |
| 2023-12-31 | 10-K | 131.314.000 | 52.154.000 | 2,94 | 787.216.000 | 700.913.000 |
| 2023-09-30 | 10-Q | 32.868.000 | -10.273.000 | -0,59 | 769.226.000 | 667.896.000 |
| 2023-06-30 | 10-Q | 26.366.000 | 2.290.000 | 0,13 | 758.105.000 | 664.892.000 |
| 2023-03-31 | 10-Q | 43.979.000 | 41.949.000 | 2,33 | 811.076.000 | 646.317.000 |
| 2022-12-31 | 10-K | 196.245.000 | -33.361.000 | -1,98 | 762.668.000 | 597.485.000 |
| 2022-09-30 | 10-Q | 59.221.000 | 404.000 | 0,02 | 1.050.605.000 | 816.298.000 |
| 2022-06-30 | 10-Q | 50.126.000 | -895.000 | -0,05 | 1.076.288.000 | 802.365.000 |
| 2022-03-31 | 10-Q | 36.516.000 | -15.385.000 | -0,91 | 1.105.184.000 | 793.192.000 |
| 2021-12-31 | 10-K | 241.544.000 | 57.138.000 | 3,31 | 1.297.590.000 | 821.159.000 |
| 2021-09-30 | 10-Q | 64.835.000 | 13.723.000 | 0,80 | 1.273.656.000 | 812.066.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Royalty | 161,0 Mio. | 108,8 Mio. | 83,9 Mio. | 72,5 Mio. | 48,9 Mio. | 21,1 % | +48,0% | |
| Intangible Royalty Assets | 132,5 Mio. | 95,3 Mio. | – | – | – | 17,3 % | +39,0% | |
| Contract Revenue And Income | 66,9 Mio. | – | – | – | – | 8,8 % | Neu | |
| Contract Revenue | 66,9 Mio. | 27,5 Mio. | 19,0 Mio. | 19,2 Mio. | 64,0 Mio. | 8,8 % | +143,4% | |
| Income From Divestiture Transactions | 53,1 Mio. | – | – | – | – | 6,9 % | Neu | |
| Material Sales Captisol | 40,2 Mio. | 30,9 Mio. | 28,4 Mio. | 104,5 Mio. | 164,3 Mio. | 5,3 % | +30,2% | |
| Material Sales Captisol Core | 40,2 Mio. | 30,9 Mio. | 28,4 Mio. | 16,4 Mio. | – | 5,3 % | +30,2% | |
| Royalty Kyprolis | 35,5 Mio. | 38,4 Mio. | 35,6 Mio. | 30,1 Mio. | 27,5 Mio. | 4,7 % | -7,4% | |
| Filspari | 32,0 Mio. | 12,2 Mio. | – | – | – | 4,2 % | +162,5% | |
| Financial Royalty Assets | 28,5 Mio. | 13,4 Mio. | – | – | – | 3,7 % | +111,7% | |
| QARZIBA | 23,7 Mio. | – | – | – | – | 3,1 % | Neu | |
| Royalty Rylaze | 13,4 Mio. | 13,7 Mio. | 13,5 Mio. | 8,8 Mio. | – | 1,7 % | -2,9% | |
| Royalty Other | 10,4 Mio. | 8,9 Mio. | 13,5 Mio. | 7,6 Mio. | 11,4 Mio. | 1,4 % | +15,9% | |
| Capvaxive | 10,1 Mio. | – | – | – | – | 1,3 % | Neu | |
| Ohtuvayre | 9,8 Mio. | – | – | – | – | 1,3 % | Neu | |
| Royalty Teriparatide Injection | 8,1 Mio. | 8,2 Mio. | 11,1 Mio. | 15,8 Mio. | – | 1,1 % | -0,9% | |
| Vaxneuvance | 7,4 Mio. | 5,2 Mio. | – | – | – | 1,0 % | +42,8% | |
| License Fees | 7,0 Mio. | 1,9 Mio. | 217.000 | 2,8 Mio. | 5,1 Mio. | 0,9 % | +259,5% | |
| Service | 6,8 Mio. | 25,5 Mio. | 615.000 | 1,1 Mio. | 23,7 Mio. | 0,9 % | -73,3% | |
| Royalty Evomela | 5,9 Mio. | 8,7 Mio. | 10,2 Mio. | 10,2 Mio. | 10,1 Mio. | 0,8 % | -31,5% | |
| Financial Royalty Other | 4,7 Mio. | – | – | – | – | 0,6 % | Neu | |
| Contract Revenue And Other Income | – | 27,5 Mio. | – | – | – | – | – | |
| Milestone | – | – | 16,8 Mio. | 9,2 Mio. | 28,7 Mio. | – | – | |
| License Fees Milestones And Other Product Other | – | – | 1,4 Mio. | 6,1 Mio. | 6,4 Mio. | – | – | |
| Material Sales Captisol COVID | – | – | – | 88,1 Mio. | – | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 08.05.2026 | 51,7 Mio. USD | -0,67 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 115,5 Mio. USD | 5,68 |
| Q2 2025 | 30.06.2025 | 08.08.2025 | 47,6 Mio. USD | 0,24 |
| Q1 2025 | 31.03.2025 | 08.05.2026 | 45,3 Mio. USD | -2,21 |
| Q3 2024 | 30.09.2024 | 07.11.2025 | 51,8 Mio. USD | -0,39 |
| Q2 2024 | 30.06.2024 | 07.11.2025 | 41,5 Mio. USD | -2,88 |
| Q1 2024 | 31.03.2024 | 07.11.2025 | 31,0 Mio. USD | 4,75 |
| Q3 2023 | 30.09.2023 | 08.11.2024 | 32,9 Mio. USD | -0,59 |
| Q2 2023 | 30.06.2023 | 08.11.2024 | 26,4 Mio. USD | 0,13 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 08.05.2026 | 10-Q | 31.03.2026 | 38 Tage | SEC » |
| 27.02.2026 | 10-K | 31.12.2025 | 58 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 08.08.2025 | 10-Q | 30.06.2025 | 39 Tage | SEC » |
| 09.05.2025 | 10-Q | 31.03.2025 | 39 Tage | SEC » |
| 28.02.2025 | 10-K | 31.12.2024 | 59 Tage | SEC » |
| 08.11.2024 | 10-Q | 30.09.2024 | 39 Tage | SEC » |
| 07.08.2024 | 10-Q | 30.06.2024 | 38 Tage | SEC » |
| 08.05.2024 | 10-Q | 31.03.2024 | 38 Tage | SEC » |
| 29.02.2024 | 10-K | 31.12.2023 | 60 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 09.08.2023 | 10-Q | 30.06.2023 | 40 Tage | SEC » |
| 08.05.2023 | 10-Q | 31.03.2023 | 38 Tage | SEC » |
| 28.02.2023 | 10-K | 31.12.2022 | 59 Tage | SEC » |
| 08.11.2022 | 10-Q | 30.09.2022 | 39 Tage | SEC » |
| 09.08.2022 | 10-Q | 30.06.2022 | 40 Tage | SEC » |
| 09.05.2022 | 10-Q | 31.03.2022 | 39 Tage | SEC » |
| 28.02.2022 | 10-K | 31.12.2021 | 59 Tage | SEC » |
| 09.11.2021 | 10-Q | 30.09.2021 | 40 Tage | SEC » |
| 03.08.2021 | 10-Q | 30.06.2021 | 34 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 24.02.2021 | 10-K | 31.12.2020 | 55 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (09.06.2026)
HOCH Abgang Schlüsselpersonen (09.06.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 17.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 27.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 14.12.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.12.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 04.11.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.08.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 29.06.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 13.06.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.01.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.07.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 28.01.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.12.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |